Quick Answer
Janux Therapeutics, Inc. reported Operating Income of -$157.67 million for fiscal year 2025.
Janux Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$157.67M | -59.5% |
| 2024 | -$98.85M | -35.4% |
| 2023 | -$72.98M | -8.8% |
| 2022 | -$67.09M | -103.7% |
| 2021 | -$32.93M | -579.9% |
| 2020 | -$4.84M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$35.25M | +1.6% | +21.9% |
| June 30, 2025 | -$45.12M | -226.4% | -29.3% |
| March 31, 2025 | -$34.90M | -73.1% | +2.6% |
| September 30, 2024 | -$35.84M | -126.7% | -159.3% |
| June 30, 2024 | -$13.82M | +33.4% | +31.4% |
| March 31, 2024 | -$20.16M | +0.6% | -27.5% |
| September 30, 2023 | -$15.81M | +12.3% | +23.8% |
| June 30, 2023 | -$20.75M | -20.2% | -2.3% |
- Janux Therapeutics, Inc. showed a decrease of -59.5% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Janux Therapeutics, Inc.’s operating income has declined by 3155.6% (from -$4.84 million to -$157.67 million).
- The most recent figure is from Janux Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: